Zhongyao Holdings (重药控股) Announces Massive RMB 20.5 Billion Financing Plan Amidst Growing Debt Concerns

Financing Plans Amidst Financial Strain

Zhongyao Holdings (重药控股), a prominent player in China's pharmaceutical sector, has unveiled an ambitious financing plan aimed at raising approximately RMB 20.5 billion by 2026. This announcement comes at a time when the company grapples with significant financial challenges, including looming short-term debts totaling RMB 19.4 billion. Despite reporting an annual profit of only RMB 300 million, the company appears to be doubling down on its financing strategies to support its extensive operations.

The company plans to leverage various financial instruments, including bank loans and bonds, to secure this hefty sum. In total, Zhongyao Holdings and its subsidiaries aim for a comprehensive financing limit of up to RMB 493 billion. This move follows a pattern of large-scale financing initiatives, with previous plans exceeding RMB 340 billion in 2023. But why is such enormous funding necessary? It appears that high accounts receivable and inventory levels are straining the company's liquidity.

Rising Debt and Operational Challenges

As of September 2025, Zhongyao Holdings reported a staggering short-term debt of RMB 184.96 billion, with a high asset-liability ratio consistently above 75% since 2020. The company’s cash flow has been increasingly negative, highlighting its insufficient self-sustaining capabilities. For instance, cash flow from operations turned negative in 2024 and continued to decline into 2025, reflecting a concerning trend for investors and stakeholders alike.

The financial strain is exacerbated by rising accounts receivable, which have surged by over 30% from 2022 to 2025. The company’s collection efficiency is deteriorating, with receivables turnover days increasing significantly during the same period. An alarming spike in credit impairment losses, up 61.97% year-over-year in the latest reporting period, is also raising red flags regarding the company's financial health.

Inventory Risks and Profitability Issues

In addition to high debts, Zhongyao Holdings faces an increasing inventory problem, with levels rising from RMB 78.63 billion in 2022 to RMB 101.64 billion in 2025. The pharmaceutical industry is characterized by rapid product turnover and short shelf life, which complicates the inventory situation further. Any market fluctuations could lead to significant write-downs, adversely affecting profitability.

Despite a growing revenue base—reportedly increasing from RMB 678.29 billion in 2022 to RMB 805.62 billion in 2024—the company's net profit has plummeted from RMB 9.52 billion to RMB 2.83 billion during the same period. This paradox of rising revenue without corresponding profit growth raises questions about the sustainability of Zhongyao Holdings' business model and its ability to effectively manage its financial obligations.

As Zhongyao Holdings navigates these turbulent waters, stakeholders will be watching closely to see whether the company's ambitious financing plans can turn around its financial fortunes or if it will continue to struggle under the weight of its mounting debts.